SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: phbolton who wrote (2860)3/19/1998 9:06:00 PM
From: Hank  Read Replies (2) of 7041
 
<<the success rate for Viagra is not public knowledge>>

Actually, it is. As of today, the PFE press releases concerning Viagra state that it is effective in 50% to 80% of MED cases, depending on the cause of impotence.

The data isn't published yet simply because it is PFE's policy not to publish research data on new drugs until they are approved by the FDA.

Vasomax stands NO chance of approval by the FDA because it is NOT more effective than Viagra. It's chance of approval in Europe is equally unlikely. ZONA can sell Vasomax in Mexico or in other third world countries but they will make little or no money. The countries are too poor and nobody there can afford to pay a premium for non-life preserving medications. SGP is trying to recoupe as much of their investment loss as they can by going along with this Mexico registration. If SGP really believed that Vasomax stood a chance of approval in either the US, Canada, or Europe, that is where their efforts would be focused. Third world countries would be an after thought. The fact that they choose to register in Mexico first is tantamount to admitting outright that Vasomax is useless.

Hank
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext